Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR1 | P21462 | 3/20 | 0.45 |
| ▸ | FPR2 | P25090 | 3/20 | 0.45 |
| ▸ | NAMPT | P43490 | 2/20 | 0.45 |
| ▸ | ENPP3 | O14638 | 4/20 | 0.45 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.45 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | CCR2 | P41597 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5638974 | 0.86 | KMT2A (0.54) | ENPP3ENPP1ENPP2MAPT | |
| SCHEMBL5639084 | 0.84 | RAB9A (0.54) | MAPT | |
| SCHEMBL5638116 | 0.83 | SMN1; SMN2 (0.50) | MAPT | |
| SCHEMBL5639457 | 0.82 | FPR2 (0.53) | FPR1FPR2TRPV1 | |
| SCHEMBL5638456 | 0.77 | NPC1 (0.50) | MAPT | |
| SCHEMBL28884238 | 0.77 | NAMPT (0.51) | FPR1FPR2NAMPTTRPV1EPHX2 | |
| SCHEMBL15336337 | 0.76 | TRPV1 (0.54) | NAMPTTRPV1MAPT | |
| SCHEMBL14306236 | 0.74 | MAPT (0.69) | NAMPTTRPV1EPHX2MAPTCNR1 | |
| SCHEMBL5638914 | 0.74 | KMT2A (0.47) | — | |
| SCHEMBL32660750 | 0.74 | TRPV1 (0.62) | NAMPTTRPV1EPHX2MAPTCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220856-B2 | Substituted quinoline CCR5 receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-05-22 | — | — | US | disclosed |
| EP-1534681-A1 | SUBSTITUTED QUINOLINE CCR5 RECEPTOR ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-06-01 | — | — | EP | disclosed |
| US-20040072818-A1 | Substituted quinoline CCR5 receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-04-15 | — | — | US | disclosed |
| WO-2004002960-A1 | SUBSTITUTED QUINOLINE CCR5 RECEPTOR ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072818-A1 | Substituted quinoline CCR5 receptor antagonists | CCR5, CXCR3, CCR2 | FPR1 107/4885FPR2 180/4885NAMPT 2154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.